<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20230721085435&amp;utm_campaign=pubmed-2&amp;v=2.17 。 9.post6+86293ac&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20230721085435&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 7 月 21 日星期五 12:54:37 +0000</lastbuilddate><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> EGFR/IGF1R 信号传导调节肥厚型心肌病的松弛</title><link/>https://pubmed.ncbi.nlm.nih.gov/37477020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>结论：我们展示了筛选心肌细胞舒张和收缩的功能调节剂的可行性，我们观察到这些参数分别受 EGFR/IGF1R、Akt、细胞周期信号传导和 FoxO（叉头盒 O 类）信号传导相关激酶的调节。将筛选数据与 HCM 患者组织中的磷酸蛋白质组学分析相结合表明，抑制 EGFR/IGF1R 信号传导是治疗 HCM 松弛的有希望的靶点。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 21 日。doi：10.1161/CIRCRESAHA.122.322133。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：舒张功能障碍是射血分数保留的心力衰竭和肥厚性心肌病 (HCM) 等疾病的核心。然而，改善心脏舒张的治疗方法很少，部分原因是对心肌细胞舒张调节剂的了解有限。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们优化并提高了空载起酥油测量的通量，并在野生型小鼠分离的成年心肌细胞中筛选了激酶抑制剂库。筛选了 157 种激酶抑制剂，并在纯合子<i>MYBPC3</i> <sub>c.2373insG</sub> HCM 小鼠模型的心肌细胞中进行了验证。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在野生型 (n=33) 心肌细胞 (n=24 563) 中筛选 157 种激酶抑制剂，结果鉴定出 17 种正性肌力药物和 21 种阳性强心剂，几乎全部都是新的。通过对 HCM 患者心肌（n=24 名 HCM 和 n=8 名供者）进行磷酸蛋白质组学分析，我们证明 EGFR/IGFR1 簇的 8 种蛋白中的 6 种的激活增加我们在小鼠 HCM (n=12) 心肌细胞 (n=2023) 中验证了该簇中的化合物。该簇中的三种化合物能够改善 HCM 心肌细胞的松弛。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们展示了筛选心肌细胞舒张和收缩的功能调节剂的可行性，我们观察到这些参数分别受 EGFR/IGF1R、Akt、细胞周期信号传导和 FoxO（叉头盒 O 类）信号传导相关激酶的调节。将筛选数据与 HCM 患者组织中的磷酸蛋白质组学分析相结合表明，抑制 EGFR/IGF1R 信号传导是治疗 HCM 松弛的有希望的靶点。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37477020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37477020</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.122.322133>10.1161/CIRCRESAHA.122.322133</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37477020</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>西拉·阿尔古尔</dc:creator><dc:creator>麦克·舒尔特</dc:creator><dc:creator>艾美·曼德斯</dc:creator><dc:creator>瓦伦汀·詹森</dc:creator><dc:creator>萨斯基亚·施洛萨雷克</dc:creator><dc:creator>理查德·德·戈伊·德·哈斯</dc:creator><dc:creator>亚历克斯·亨尼曼</dc:creator><dc:creator>桑德·R·皮尔斯玛</dc:creator><dc:creator>康妮·R·希门尼斯</dc:creator><dc:creator>米歇尔·米歇尔</dc:creator><dc:creator>露西·开利</dc:creator><dc:creator>米歇尔·赫尔姆斯</dc:creator><dc:creator>乔兰达·范德维尔登</dc:creator><dc:creator>迪德里克·WD·库斯特</dc:creator><dc:date>2023-07-21</dc:date><dc:source>流通研究</dc:source><dc:title>EGFR/IGF1R 信号传导调节肥厚型心肌病的松弛</dc:title><dc:identifier>下午：37477020</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322133</dc:identifier></item><item><title>肺栓塞的新型预测模型：从二分算法到个性化可能性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37475706/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 21:ehad392.doi: 10.1093/eurheartj/ehad392. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37475706/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37475706</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad392>10.1093/eurheartj/ehad392</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37475706</guid><pubDate> Fri, 21 Jul 2023 06:00:00 -0400</pubDate><dc:creator>托马斯·A·泽尔尼克</dc:creator><dc:creator>艾琳·M·朗</dc:creator><dc:date>2023-07-21</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>肺栓塞的新型预测模型：从二分算法到个性化可能性</dc:title><dc:identifier>下午：37475706</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad392</dc:identifier></item><item><title>急性冠状动脉综合征和经皮冠状动脉介入治疗中双重抗血小板治疗的降级或缩写：冠状动脉血栓形成国际专家组的共识声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37474795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>对于接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者，传统的双重抗血小板治疗 (DAPT) 包括阿司匹林和强效 P2Y 嘌呤受体 12 (P2Y(12)) 抑制剂（普拉格雷或替格瑞洛），疗程为 12 个月。）常规剂量的抑制剂可以... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 7 月 20 日。doi：10.1038/s41569-023-00901-2。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y purinoceptor 12 (P2Y <sub>12</sub> ) inhibitor (prasugrel or ticagrelor) for 12 months. Although this approach reduces ischaemic risk, patients are exposed to a substantial risk of bleeding. Strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y <sub>12</sub> inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. Either strategy requires assessment of the ischaemic and bleeding risks of each individual. De-escalation of DAPT intensity can reduce bleeding without increasing ischaemic events and can be guided by platelet function testing or genotyping. Abbreviation of DAPT duration after 1-6 months, followed by monotherapy with aspirin or a P2Y <sub>12</sub> inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk. However, these two strategies have not yet been compared in a head-to-head clinical trial. In this Consensus Statement, we summarize the evidence base for these treatment approaches, provide guidance on the assessment of ischaemic and bleeding risks, and provide consensus statements from an international panel of experts to help clinicians to optimize these DAPT approaches for individual patients to improve outcomes.</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37474795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37474795</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00901-2>10.1038/s41569-023-00901-2</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37474795</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>戴安娜·戈罗格</dc:creator><dc:creator>何塞·路易斯·费雷罗</dc:creator><dc:creator>英戈·阿伦斯</dc:creator><dc:creator>亚子纯也</dc:creator><dc:creator>托比亚斯·盖斯勒</dc:creator><dc:creator>西格伦·霍尔沃森</dc:creator><dc:creator>库尔特·胡贝尔</dc:creator><dc:creator>郑英勋</dc:creator><dc:creator>埃利亚诺·P·纳瓦雷塞</dc:creator><dc:creator>安德里亚·鲁博利</dc:creator><dc:creator>德克·西宾</dc:creator><dc:creator>乔兰塔·M·西勒-马图拉</dc:creator><dc:creator>罗伯特·F·斯托里</dc:creator><dc:creator>——杰克·WC·谭</dc:creator><dc:creator>朱里恩·M·滕伯格</dc:creator><dc:creator>马可·瓦尔吉米利</dc:creator><dc:creator>克里斯托夫·范登布里埃勒</dc:creator><dc:creator>格雷戈里·YH·利普</dc:creator><dc:date>2023-07-20</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>急性冠状动脉综合征和经皮冠状动脉介入治疗中双重抗血小板治疗的降级或缩写：冠状动脉血栓形成国际专家组的共识声明</dc:title><dc:identifier>下午：37474795</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00901-2</dc:identifier></item><item><title> 2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠心病患者管理指南：美国心脏协会/美国心脏病学会临床实践指南联合委员会报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/37471501/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description> AIM 《2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠心病患者管理指南》更新并巩固了自《2012 年 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS 稳定型缺血性心脏病患者诊断和管理指南》以及相应的《2014 年 ACC/AHA/AATS/PCNA/SCAI/S TS 焦点》以来的新证据编辑了稳定型缺血性心脏病患者诊断和管理指南的更新。”方法综合... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 20 日。doi：10.1161/CIR.0000000000001168。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> AIM 《2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠心病患者管理指南》更新并巩固了自《2012 年 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS 稳定型缺血性心脏病患者诊断和管理指南》以及相应的《2014 年 ACC/AHA/AATS/PCNA/SCAI/S TS 焦点》以来的新证据方法 从 2021 年 9 月至 2022 年 5 月进行了全面的文献检索。确定了对人类参与者进行的临床研究、系统评价和荟萃分析以及其他证据，这些证据以英文发表于 MEDLINE（通过 PubMed）、EMBASE、Cochrane 图书馆、医疗保健研究和质量机构以及与本指南相关的其他选定数据库。相关主题包括治疗决策的一般方法、旨在减少症状和未来心血管事件的指南指导的管理和治疗、与慢性冠心病患者血运重建有关的决策、特殊人群的管理建议、患者随访和监测、证据差距以及未来需要研究的领域。还为临床医生提供了健康数据、成本价值建议。之前发布的指南中的许多建议已用新证据进行了更新，并在已发布数据的支持下创建了新的建议。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37471501/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37471501</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001168>10.1161/CIR.0000000000001168</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37471501</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>萨利姆·维拉尼</dc:creator><dc:creator>L克里斯汀·纽比</dc:creator><dc:creator>苏珊娜诉阿诺德</dc:creator><dc:creator>维拉·比特纳</dc:creator><dc:creator>拉普林斯·C·布鲁尔</dc:creator><dc:creator>苏珊·哈利·德米特</dc:creator><dc:creator>——戴夫·迪克森</dc:creator><dc:creator>威廉·费伦</dc:creator><dc:creator>贝弗利·赫斯</dc:creator><dc:creator>希瑟·M·约翰逊</dc:creator><dc:creator>Dhruv S Kazi更多</dc:creator><dc:creator>达瓦尔·科尔特</dc:creator><dc:creator>达拉姆·J·昆巴尼</dc:creator><dc:creator>吉姆·洛法索更多</dc:creator><dc:creator>德鲁夫·马赫塔</dc:creator><dc:creator>丹尼尔·B·马克</dc:creator><dc:creator>Margo Minissian更多</dc:creator><dc:creator>——安-玛丽·纳瓦尔</dc:creator><dc:creator>阿米特·R·帕特尔</dc:creator><dc:creator>玛丽安·R·钢琴</dc:creator><dc:creator>法蒂玛·罗德里格斯</dc:creator><dc:creator>艾米·W·塔尔伯特</dc:creator><dc:creator>维维安尼·R·塔奎蒂</dc:creator><dc:creator>兰德尔·J·托马斯</dc:creator><dc:creator>肖恩·范·迪彭</dc:creator><dc:creator>芭芭拉·威金斯</dc:creator><dc:creator>——马琳·S·威廉姆斯</dc:creator><dc:date>2023-07-20</dc:date><dc:source>循环</dc:source><dc:title>2023 年 AHA/ACC/ACCP/ASPC/NLA/PCNA 慢性冠心病患者管理指南：美国心脏协会/美国心脏病学会临床实践指南联合委员会报告</dc:title><dc:identifier>下午：37471501</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001168</dc:identifier></item><item><title>更正：重新调整药物用于治疗 COVID-19 及其心血管表现</title><link/>https://pubmed.ncbi.nlm.nih.gov/37471489/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023年7月21日；133(3):e49.doi: 10.1161/RES.0000000000000623.Epub 2023年7月20日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37471489/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37471489</a> | DOI： <a href=https://doi.org/10.1161/RES.0000000000000623>10.1161/RES.0000000000000623</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37471489</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-20</dc:date><dc:source>流通研究</dc:source><dc:title>更正：重新调整药物用于治疗 COVID-19 及其心血管表现</dc:title><dc:identifier>下午：37471489</dc:identifier><dc:identifier> doi:10.1161/RES.0000000000000623</dc:identifier></item><item><title>更正：SIRT6 通过保留射血分数来减轻糖尿病患者的心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/37471488/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023年7月21日；133(3):e48.doi: 10.1161/RES.0000000000000622.Epub 2023年7月20日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37471488/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37471488</a> | DOI： <a href=https://doi.org/10.1161/RES.0000000000000622>10.1161/RES.0000000000000622</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37471488</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-20</dc:date><dc:source>流通研究</dc:source><dc:title>更正：SIRT6 通过保留射血分数来减轻糖尿病患者的心力衰竭</dc:title><dc:identifier>下午：37471488</dc:identifier><dc:identifier> doi:10.1161/RES.0000000000000622</dc:identifier></item><item><title> p53 位于心脏成纤维细胞增殖和激活的交叉点：答案和问题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37471487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 21 日；133(3):288-290。doi: 10.1161/CIRCRESAHA.123.323209。Epub 2023 年 7 月 20 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37471487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37471487</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323209>10.1161/CIRCRESAHA.123.323209</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37471487</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>亚历山德拉·吉戈</dc:creator><dc:creator>彼得罗·阿梅里</dc:creator><dc:date>2023-07-20</dc:date><dc:source>流通研究</dc:source><dc:title>p53 位于心脏成纤维细胞增殖和激活的交叉点：答案和问题</dc:title><dc:identifier>下午：37471487</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323209</dc:identifier></item><item><title> HDAC 内源性负调节因子可缓解心脏纤维化</title><link/>https://pubmed.ncbi.nlm.nih.gov/37471486/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 21 日；133(3):252-254。doi: 10.1161/CIRCRESAHA.123.323211。Epub 2023 年 7 月 20 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37471486/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37471486</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323211>10.1161/CIRCRESAHA.123.323211</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37471486</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·P·拉扎罗普洛斯</dc:creator><dc:creator>约翰·埃尔罗德</dc:creator><dc:date>2023-07-20</dc:date><dc:source>流通研究</dc:source><dc:title>HDAC 内源性负调节因子可缓解心脏纤维化</dc:title><dc:identifier>下午：37471486</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323211</dc:identifier></item><item><title>认识第一作者</title><link/>https://pubmed.ncbi.nlm.nih.gov/37471484/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 21 日；133(3):198-199。doi: 10.1161/RES.0000000000000625。Epub 2023 年 7 月 20 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37471484/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37471484</a> | DOI： <a href=https://doi.org/10.1161/RES.0000000000000625>10.1161/RES.0000000000000625</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37471484</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:date> 2023-07-20</dc:date><dc:source>流通研究</dc:source><dc:title>认识第一作者</dc:title><dc:identifier>下午：37471484</dc:identifier><dc:identifier> doi:10.1161/RES.0000000000000625</dc:identifier></item><item><title>慢性冠心病指南</title><link/>https://pubmed.ncbi.nlm.nih.gov/37471475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 7 月 20 日。doi：10.1161/CIRCULATIONAHA.123.064623。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37471475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37471475</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064623>10.1161/CIRCULATIONAHA.123.064623</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37471475</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>苏尼尔·V·拉奥</dc:creator><dc:creator>哈莫尼·R·雷诺兹</dc:creator><dc:creator>——朱迪思·S·霍克曼</dc:creator><dc:date>2023-07-20</dc:date><dc:source>循环</dc:source><dc:title>慢性冠心病指南</dc:title><dc:identifier>下午：37471475</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064623</dc:identifier></item><item><title>球囊肺血管成形术治疗慢性血栓栓塞性肺动脉高压：ESC工作组关于肺循环和右心室功能的临床共识声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37470202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description> 2022 年欧洲心脏病学会 (ESC)/欧洲呼吸学会 (ERS) 肺动脉高压 (PH) 诊断和治疗指南中描述的慢性血栓栓塞性肺动脉高压 (CTEPH) 目前的治疗方案包括肺动脉内膜切除术 (PEA)、球囊肺血管成形术 (BPA) 和医学科学相结合的多模式方法，以针对主要血管肺血管病变和微血管病变。如今，BPA >;1700... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 20:ehad413.doi: 10.1093/eurheartj/ehad413. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> 2022 年欧洲心脏病学会 (ESC)/欧洲呼吸学会 (ERS) 肺动脉高压 (PH) 诊断和治疗指南中描述的慢性血栓栓塞性肺动脉高压 (CTEPH) 目前的治疗方案包括肺动脉内膜切除术 (PEA)、球囊肺血管成形术 (BPA) 和医学科学相结合的多模式方法，以针对主要血管肺血管病变。如今，来自美国亚洲中心的文献报道了超过 1700 名患者的 BPA以及欧洲；更多的患者在文献报道之外接受治疗。随着 BPA 成为 CTEPH 患者常规护理的一部分，安全有效的护理提供基准变得越来越重要。德尔菲法用于非证据基础的陈述。首先，提供了解剖学命名法和血管病变的描述。其次，概述了完全 BPA 的治疗目标和定义。第三，提出了并发症的定义，这可能是涉及 BPA 的研究标准化报告的基础。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37470202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37470202</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad413>10.1093/eurheartj/ehad413</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37470202</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>艾琳·M·朗</dc:creator><dc:creator>阿恩·K·安德烈森</dc:creator><dc:creator>阿斯格·安徒生</dc:creator><dc:creator>海伦·布瓦伊斯特</dc:creator><dc:creator>格里·科格兰</dc:creator><dc:creator>皮拉尔·埃斯克里巴诺-苏比亚斯</dc:creator><dc:creator>Pavel Jansa更多</dc:creator><dc:creator>格热戈日·科佩克</dc:creator><dc:creator>马尔钦·库尔兹纳</dc:creator><dc:creator>松原博美</dc:creator><dc:creator>伯恩哈德·克里斯蒂安·迈耶</dc:creator><dc:creator>马西米利亚诺·帕拉齐尼</dc:creator><dc:creator>马可·C·波斯特</dc:creator><dc:creator>皮奥特·普鲁什奇克</dc:creator><dc:creator>洛伦兹·拉贝尔</dc:creator><dc:creator>马雷克·罗伊克</dc:creator><dc:creator>斯蒂芬·罗森克兰兹</dc:creator><dc:creator>克里斯托夫·维登罗斯</dc:creator><dc:creator>卡罗·雷德林·韦尔勒</dc:creator><dc:creator>菲利普·布雷诺</dc:creator><dc:date>2023-07-20</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>球囊肺血管成形术治疗慢性血栓栓塞性肺动脉高压：ESC工作组关于肺循环和右心室功能的临床共识声明</dc:title><dc:identifier>下午：37470202</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad413</dc:identifier></item><item><title> Danicamtiv 增加肌球蛋白募集并改变心肌的跨桥循环</title><link/>https://pubmed.ncbi.nlm.nih.gov/37470183/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>结论：正如 Danicamtiv 的详细研究所证明的那样，增加肌球蛋白募集和改变跨桥循环是增加心肌力和钙敏感性的两种机制。肌球蛋白激活剂如 Danicamtiv 可以治疗遗传性扩张型心肌病的致病性低收缩表型。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 7 月 20 日。doi：10.1161/CIRCRESAHA.123.322629。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：调节肌球蛋白功能是心肌病患者的一种新型治疗方法。Danicamtiv 是一种新型肌球蛋白激活剂，具有良好的临床前数据，目前正在进行临床试验。虽然已知 danicamtiv 可以增加力量和心肌细胞收缩力而不影响钙水平，但缺乏关于其作用方式的详细机制研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用透化的猪心脏组织和肌原纤维进行X射线衍射和力学测量，并使用遗传性扩张型心肌病小鼠模型来评估danicamtiv纠正收缩缺陷的能力。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：Danicamtiv 通过增加处于开启状态的肌球蛋白数量和减慢跨桥周转来增加力和钙敏感性。我们的详细分析表明，抑制 ADP 释放会导致跨桥周转减少，横桥保持更长的附着时间并延长肌原纤维松弛。Danicamtiv 纠正了脱膜组织中钙敏感性的降低、完整心脏组织中的异常抽搐和幅度动力学以及整个器官中射血分数的降低。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：正如 Danicamtiv 的详细研究所证明的那样，增加肌球蛋白募集和改变跨桥循环是增加心肌力和钙敏感性的两种机制。肌球蛋白激活剂如 Danicamtiv 可以治疗遗传性扩张型心肌病的致病性低收缩表型。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37470183/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37470183</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.322629>10.1161/CIRCRESAHA.123.322629</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37470183</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>克里斯蒂娜·B·库克</dc:creator><dc:creator>萨菲·莫兰</dc:creator><dc:creator>——凯拉·L·特纳</dc:creator><dc:creator>马伟康</dc:creator><dc:creator>艾米·马丁森</dc:creator><dc:creator>加林娜·弗林特</dc:creator><dc:creator>林琪</dc:creator><dc:creator>高承前</dc:creator><dc:creator>郑雅涵</dc:creator><dc:creator>蒂莫西·麦克米伦</dc:creator><dc:creator>克里斯蒂安·曼德里基</dc:creator><dc:creator>马克斯·马奥尼-谢弗</dc:creator><dc:creator>——杰里米·C·弗里曼</dc:creator><dc:creator>伊利亚·加布里埃拉·科斯塔莱斯·阿里纳斯</dc:creator><dc:creator>涂安宇</dc:creator><dc:creator>托马斯·C·欧文</dc:creator><dc:creator>迈克尔·吉夫斯</dc:creator><dc:creator>——伯特兰·C·W·坦纳</dc:creator><dc:creator>——迈克尔·雷尼尔</dc:creator><dc:creator>詹妮弗·戴维斯</dc:creator><dc:creator>法里德·穆萨维·哈拉米</dc:creator><dc:date>2023-07-20</dc:date><dc:source>流通研究</dc:source><dc:title>Danicamtiv 增加肌球蛋白募集并改变心肌的跨桥循环</dc:title><dc:identifier>下午：37470183</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.322629</dc:identifier></item><item><title>仪器变量、计算机试验模拟和心脏病学前沿分析：能力越大，责任越大</title><link/>https://pubmed.ncbi.nlm.nih.gov/37470166/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Jul 20:ehad248.doi: 10.1093/eurheartj/ehad248. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37470166/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37470166</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad248>10.1093/eurheartj/ehad248</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37470166</guid><pubDate> Thu, 20 Jul 2023 06:00:00 -0400</pubDate><dc:creator>布里多格·尼克·奥达·布伊</dc:creator><dc:creator>约翰·威廉·麦克沃伊</dc:creator><dc:date>2023-07-20</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>仪器变量、计算机试验模拟和心脏病学前沿分析：能力越大，责任越大</dc:title><dc:identifier>下午：37470166</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad248</dc:identifier></item><item><title>回复：在没有真正的超声心动图评估的情况下诊断假体与患者不匹配：我们的研究是否正确？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468194/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):e29.doi: 10.1016/j.jacc.2023.05.029。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468194/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37468194</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.029>10.1016/j.jacc.2023.05.029</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468194</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·迪斯莫尔</dc:creator><dc:creator>娜塔莉·格拉泽</dc:creator><dc:creator>安德斯·佛朗哥-塞雷塞达</dc:creator><dc:creator>乌尔里克·萨蒂皮</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>回复：在没有真正的超声心动图评估的情况下诊断假体与患者不匹配：我们的研究是否正确？</dc:title><dc:identifier>下午：37468194</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.029</dc:identifier></item><item><title>在没有真正的超声心动图评估的情况下诊断假体与患者不匹配：我们的研究是否错误？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468193/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):e27.doi: 10.1016/j.jacc.2023.05.027。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468193/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37468193</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.027>10.1016/j.jacc.2023.05.027</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468193</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>博杨</dc:creator><dc:creator>-爱德华·P·陈</dc:creator><dc:creator>戈拉夫·艾拉瓦迪</dc:creator><dc:creator>——迈克尔·J·里尔登</dc:creator><dc:creator>G-迈克尔·迪布</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>在没有真正的超声心动图评估的情况下诊断假体与患者不匹配：我们的研究是否错误？</dc:title><dc:identifier>下午：37468193</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.027</dc:identifier></item><item><title>左心耳封堵术与直接口服抗凝剂治疗心房颤动的秋季结局</title><link/>https://pubmed.ncbi.nlm.nih.gov/37468192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):379-381.doi:10.1016/j.jacc.2023.05.032。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37468192</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.032>10.1016/j.jacc.2023.05.032</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468192</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>邓文俊</dc:creator><dc:creator>穆萨·曼苏尔</dc:creator><dc:creator>宋波</dc:creator><dc:creator>侯海曼</dc:creator><dc:creator>刘凯</dc:creator><dc:creator>徐玉明</dc:creator><dc:creator>大卫·麦克穆林</dc:creator><dc:creator>费迪南多·S·博南诺</dc:creator><dc:creator>罗英华</dc:creator><dc:creator>明明宁</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>左心耳封堵术与直接口服抗凝剂治疗心房颤动的秋季结局</dc:title><dc:identifier>下午：37468192</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.032</dc:identifier></item><item><title>植入式心脏复律除颤器的开发：JACC 的历史性突破</title><link/>https://pubmed.ncbi.nlm.nih.gov/37468191/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>植入式心律转复除颤器 (ICD) 代表了变革性技术，可以说是 50 年来心血管医学领域最重大的进步。先驱者 Mirowski 和 Mower 的远见和决心是这一巨大成就的基础，他们在资源有限的情况下开展工作，并面临来自医疗机构的怀疑/批评。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):353-373.doi:10.1016/j.jacc.2023.04.056。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">植入式心律转复除颤器 (ICD) 代表了变革性技术，可以说是 50 年来心血管医学领域最重大的进步。先驱者 Mirowski 和 Mower 的远见和决心是这一巨大成就的基础，他们在资源有限的情况下，面对来自医疗机构的怀疑/批评。室颤 (1980) 获得了美国食品和药物管理局的批准。经静脉导线系统将 ICD 从基于开胸术的二级预防转变为一级预防全世界无数患者都使用了猝死装置。前瞻性随机对照试验显示，ICD 的接受度优于抗心律失常药物。前瞻性随机对照试验显示，死亡率优于抗心律失常药物。只要有无畏的想象力，追求与公认智慧相冲突的新想法，医学领域就可以克服一切困难取得进展。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468191/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37468191</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.04.056>10.1016/j.jacc.2023.04.056</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468191</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>巴里·J·马龙</dc:creator><dc:creator>马克·埃斯蒂斯</dc:creator><dc:creator>伊森·J·罗文</dc:creator><dc:creator>马丁·S·马龙</dc:creator><dc:creator>——马修·R·雷诺兹</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>植入式心脏复律除颤器的开发：JACC 的历史性突破</dc:title><dc:identifier>下午：37468191</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.056</dc:identifier></item><item><title> Omega-3 脂肪酸与心房颤动的风险：大鱼还是小鱼？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468190/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):350-352.doi:10.1016/j.jacc.2023.05.026。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468190/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37468190</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.026>10.1016/j.jacc.2023.05.026</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468190</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>克里斯蒂·M·巴兰坦</dc:creator><dc:creator>贾晓明</dc:creator><dc:date>2023-07-19</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>Omega-3 脂肪酸与心房颤动的风险：大鱼还是小鱼？</dc:title><dc:identifier>下午：37468190</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.026</dc:identifier></item><item><title> Omega-3 脂肪酸生物标志物和心房颤动事件</title><link/>https://pubmed.ncbi.nlm.nih.gov/37468189/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230721085435&amp;v=2.17.9.post6+86293ac<description>结论：体内 omega-3 脂肪酸（包括 EPA、DPA、DHA 和 EPA+DHA）水平与 AF 风险增加无关。我们的数据表明，习惯性饮食摄入 omega-3 脂肪酸对于 AF 风险是安全的。再加上这些脂肪酸在预防不良冠状动脉事件方面的已知益处，我们的研究表明，当前建议食用鱼/omega-3 脂肪酸的饮食指南可以维持下去。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 7 月 25 日；82(4):336-349.doi:10.1016/j.jacc.2023.05.024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：omega-3 脂肪酸与心房颤动 (AF) 之间的关系仍存在争议。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在确定血液或脂肪组织中二十碳五烯酸 (EPA)、二十二碳五烯酸 (DPA) 和二十二碳六烯酸 (DHA) 水平与 AF 发生的前瞻性关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们使用了来自 17 项前瞻性队列研究的全球联盟的参与者级别数据，每项研究都有血液或脂肪组织 omega-3 脂肪酸水平和 AF 结果的基线数据。每项参与研究均使用预先指定的分析计划进行从头分析，该计划具有暴露、结果、协变量和亚组的统一定义。使用逆方差加权荟萃分析汇总关联。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在来自 17 个队列的 54,799 名参与者中，经过中位 13.3 年的随访，确定了 7,720 例 AF 事件。在多变量分析中，EPA 水平与 AF 事件无关，每五分位数范围的 HR（即第 90 个百分位数和第 10 个百分位数之间的差异）为 1.00（95% CI：0.95-1.05）。 DPA、DHA 和 EPA+DHA 的较高水平分别为 0.89 (95% CI: 0.83-0.95)、0.90 (95% CI: 0.85-0.96) 和 0.93 (95% CI: 0.87-0.99)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：体内 omega-3 脂肪酸（包括 EPA、DPA、DHA 和 EPA+DHA）水平与 AF 风险增加无关。我们的数据表明，习惯性饮食摄入 omega-3 脂肪酸对于 AF 风险是安全的。再加上这些脂肪酸在预防不良冠状动脉事件方面的已知益处，我们的研究表明，当前建议食用鱼/omega-3 脂肪酸的饮食指南可以维持下去。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37468189/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37468189</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.024>10.1016/j.jacc.2023.05.024</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37468189</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator>钱方舟</dc:creator><dc:creator>——内森·廷特尔</dc:creator><dc:creator>保罗·詹森</dc:creator><dc:creator>罗森·N·勒梅特</dc:creator><dc:creator>今村文明</dc:creator><dc:creator>托比亚斯·鲁德霍尔姆·费尔德赖希</dc:creator><dc:creator>莎拉·奥普纳·野村</dc:creator><dc:creator>关伟华</dc:creator><dc:creator>费代丽卡·拉古兹</dc:creator><dc:creator>金恩静</dc:creator><dc:creator>于尔基·维尔塔宁</dc:creator><dc:creator>玛琳卡·斯图尔</dc:creator><dc:creator>克里斯蒂安·博克</dc:creator><dc:creator>平川阳一郎</dc:creator><dc:creator>米歇尔·L·奥多诺霍</dc:creator><dc:creator>阿莱克斯·萨拉·维拉</dc:creator><dc:creator>安德烈斯·阿迪森·科拉特</dc:creator><dc:creator>孙琪</dc:creator><dc:creator>埃里克·B·里姆</dc:creator><dc:creator>Bruce M Psaty更多</dc:creator><dc:creator>苏珊·R·赫克伯特</dc:creator><dc:creator>尼塔·G·福鲁希</dc:creator><dc:creator>尼古拉斯·J·韦勒姆</dc:creator><dc:creator>马蒂·马克伦德</dc:creator><dc:creator>Ulf Risérus</dc:creator><dc:creator> Lars Lind</dc:creator><dc:creator> Johan Ärnlöv</dc:creator><dc:creator> Parveen Garg</dc:creator><dc:creator> Michael Y Tsai</dc:creator><dc:creator> James Pankow</dc:creator><dc:creator> Jeffrey R Misialek</dc:creator><dc:creator> Bruna Gigante</dc:creator><dc:creator> Karin Leander</dc:creator><dc:creator> Julie A Pester</dc:creator><dc:creator> Christine M Albert</dc:creator><dc:creator> Maryam Kavousi</dc:creator><dc:creator> Arfan Ikram</dc:creator><dc:creator> Trudy Voortman</dc:creator><dc:creator> Erik B Schmidt</dc:creator><dc:creator> Toshiharu Ninomiya</dc:creator><dc:creator> David A Morrow</dc:creator><dc:creator> Antoni Bayés-Genís</dc:creator><dc:creator> James H O&#39;Keefe</dc:creator><dc:creator> Kwok Leung Ong</dc:creator><dc:creator> Jason HY Wu</dc:creator><dc:creator> Dariush Mozaffarian</dc:creator><dc:creator> William S Harris</dc:creator><dc:creator> David S Siscovick</dc:creator><dc:creator> Fatty Acids and Outcomes Research Consortium (FORCE)</dc:creator><dc:date> 2023-07-19</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation</dc:title><dc:identifier> pmid:37468189</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.024</dc:identifier></item><item><title> Epicardial Adipose-Derived miR92a-3p: Stress Reduction Therapy?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468188/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230721085435&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 25;82(4):333-335. doi: 10.1016/j.jacc.2023.05.030.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37468188/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37468188</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.030>10.1016/j.jacc.2023.05.030</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37468188</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Timothy P Fitzgibbons</dc:creator><dc:date> 2023-07-19</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Epicardial Adipose-Derived miR92a-3p: Stress Reduction Therapy?</dc:title><dc:identifier> pmid:37468188</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.030</dc:identifier></item><item><title> Role of Human Epicardial Adipose Tissue-Derived miR-92a-3p in Myocardial Redox State</title><link/> https://pubmed.ncbi.nlm.nih.gov/37468187/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230721085435&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: EAT-derived miRNAs exert paracrine effects on the human heart. Indeed miR-92a-3p suppresses the wingless-type MMTV integration site family, member 5a/Rac1/NADPH oxidase axis and improves the myocardial redox state. EAT-derived miR-92a-3p is related to improved clinical outcomes and is a rational therapeutic target for the prevention and treatment of obesity-related heart disease. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Jul 25;82(4):317-332. doi: 10.1016/j.jacc.2023.05.031.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Visceral obesity is directly linked to increased cardiovascular risk, including heart failure. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: This study explored the ability of human epicardial adipose tissue (EAT)-derived microRNAs (miRNAs) to regulate the myocardial redox state and clinical outcomes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This study screened for miRNAs expressed and released from human EAT and tested for correlations with the redox state in the adjacent myocardium in paired EAT/atrial biopsy specimens from patients undergoing cardiac surgery. Three miRNAs were then tested for causality in an in vitro model of cardiomyocytes. At a clinical level, causality/directionality were tested using genome-wide association screening, and the underlying mechanisms were explored using human biopsy specimens, as well as overexpression of the candidate miRNAs and their targets in vitro and in vivo using a transgenic mouse model. The final prognostic value of the discovered targets was tested in patients undergoing cardiac surgery, followed up for a median of 8 years. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: EAT miR-92a-3p was related to lower oxidative stress in human myocardium, a finding confirmed by using genetic regulators of miR-92a-3p in the human heart and EAT. miR-92a-3p reduced nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase-derived superoxide (O <sub>2</sub> <sup>.-</sup> ) by targeting myocardial expression of WNT5A, which regulated Rac1-dependent activation of NADPH oxidases. Finally, high miR-92a-3p levels in EAT were independently related with lower risk of adverse cardiovascular events. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: EAT-derived miRNAs exert paracrine effects on the human heart. Indeed miR-92a-3p suppresses the wingless-type MMTV integration site family, member 5a/Rac1/NADPH oxidase axis and improves the myocardial redox state. EAT-derived miR-92a-3p is related to improved clinical outcomes and is a rational therapeutic target for the prevention and treatment of obesity-related heart disease.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37468187/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230721085435&v=2.17.9.post6+86293ac">37468187</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.031>10.1016/j.jacc.2023.05.031</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37468187</guid><pubDate> Wed, 19 Jul 2023 06:00:00 -0400</pubDate><dc:creator> Maria Cristina Carena</dc:creator><dc:creator> Ileana Badi</dc:creator><dc:creator> Murray Polkinghorne</dc:creator><dc:creator> Ioannis Akoumianakis</dc:creator><dc:creator> Costas Psarros</dc:creator><dc:creator> Elizabeth Wahome</dc:creator><dc:creator> Christos P Kotanidis</dc:creator><dc:creator> Nadia Akawi</dc:creator><dc:creator> Alexios S Antonopoulos</dc:creator><dc:creator> Jagat Chauhan</dc:creator><dc:creator> Rana Sayeed</dc:creator><dc:creator> George Krasopoulos</dc:creator><dc:creator> Vivek Srivastava</dc:creator><dc:creator> Shakil Farid</dc:creator><dc:creator> Nicholas Walcot</dc:creator><dc:creator> Gillian Douglas</dc:creator><dc:creator> Keith M Channon</dc:creator><dc:creator> Barbara Casadei</dc:creator><dc:creator> Charalambos Antoniades</dc:creator><dc:date> 2023-07-19</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Role of Human Epicardial Adipose Tissue-Derived miR-92a-3p in Myocardial Redox State</dc:title><dc:identifier> pmid:37468187</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.031</dc:identifier></item></channel></rss>